Hammermeldungen des "Profs"
Latest News
--------------------------------------------------------------------------------
Artificial Life Announces Securities Traded on OTC BB
NEW YORK, Aug 20, 2001 /PRNewswire via COMTEX/ -- New York based Artificial
Life Inc. (OTC Bulletin Board: ALIF), a leading provider of award winning
intelligent software robot (bot) technology, announced today that its common
stock will be traded on NASDAQ`s Over The Counter bulletin board. Following this
announcement, the Company`s ticker symbol will stay the same `ALIF`.
The announcement follows a notification from NASDAQ of Friday, August 17, 2001,
4:15 p.m. that the Company`s common stock would be de-listed from the NASDAQ
stock exchange effective as of the open of business Monday, August 20, 2001.
"We disagree with this decision as we had presented a concise and effective plan
but were not granted the requested 90 day grace period after the hearing to
comply with the listing requirements. NASDAQ is using its discretion to de-list
the Company at a time when we just turned the Company around and made it
profitable. That`s hard to understand," said Eberhard Schoeneburg, CEO
Artificial Life, Inc.
The Company noted that it plans to appeal the decision.
The Company further announced that it will continue to evaluate its options with
respect to listing its securities with other stock exchanges
--------------------
Artificial Life Expands Into Biotech, Genomics and Pharmaceutical Applications
NEW YORK, Aug 21, 2001 /PRNewswire via COMTEX/ -- New York based Artificial
Life Inc. (OTC Bulletin Board: ALIF), a leading provider of award-winning
intelligent software robot (bot) technology, announced today that it will expand
its research and business activities towards deploying and commercializing its
artificial life algorithms and bot technology into biotech, genomics and
pharmaceutical applications. The Company also announced that it plans to prepare
patent applications in this area.
The new business activities will concentrate on
-- Bot and agent based data access and data understanding
-- Neural network based biological and pharmaceutical data-mining
-- Genetic programming
-- Simulation of cell assemblies and stem cell development patterns
-- Lindenmayer-Systems and Cellular Automata simulations of life-like
systems
Web-based demonstrations of some Artificial Life algorithms and simulations
(such as 1-dimensional and 2-dimensional cellular automata) and L-Systems to
simulate plant growth patterns can be found and tested in the
products/technology section of the Company`s website at: www.artificial-
life.com
"Our corporate vision has always been to apply knowledge and algorithms derived
from the study of living systems such as the human brain and the computerized
simulation of life-like systems (from which the Company`s name `Artificial Life`
derives) to solve certain real life problems. Artificial Life is able to
simulate life-like cell formation and abstract cell growth and behavior patterns
of cell formations to a certain degree based on distributed computer systems
simulations. This allows us to do fundamental (stem) cell research without
raising ethical concerns. In addition, our bot technology can be used to query
and analyze huge data files in natural language," explained Eberhard
Schoeneburg, CEO and founder of Artificial Life.
Mr. Schoeneburg is a former Professor for industrial applications of neural
systems and artificial intelligence and author of several books about neural
networks and genetic algorithms and evolution theory.
"The advantage of our technology is that it is versatile and flexible. It can
easily be applied and adapted to all kinds of difficult scientific and economic
problems. The intelligence of our algorithms and the natural language
understanding capabilities of our agent/bot technology is the basis for this
versatility and flexibility. For our algorithms and bots it doesn`t really
matter whether the underlying data relates to financial markets data, to human
genome data or to stem cell research. These areas all represent complex data
that has to be analyzed fast, intelligently and in an automated way. We are,
therefore, confident that our technology has tremendous potential in the biotech
and related industries. In particular, the stem cell and genomics research and
the data mining related to the data increasingly pouring out of the current
research projects and databases such as the human genome project, provide for a
wide variety of applications of our bots and algorithms," said Andreas
Buehlmeier, CTO of Artificial Life.
"We constantly have to re-assess the revenue potentials of all of our business
activities and continue to improve efficiency and reduce overhead. After the
re-structuring of the company we are now able to carefully expand again into
areas in which our technology can make a difference and may generate major
revenues for us. That`s why we have decided to take these steps now at a
development stage of the market where we may become a significant player. In
addition, we are also currently evaluating and investigating partnerships and
investments in this promising area," said P. Chin Lim, CFO of
Artificial Life, Inc.
About Artificial Life Founded in 1994, Artificial Life, Inc. (OTC Bulletin
Board: ALIF) develops, markets, and supports intelligent software robots. The
company offers a variety of unique and award-winning bot-based product suites.
Major customers of Artificial Life include, among others, Advance Bank, Credit
Suisse First Boston, Eagle Star, Liechtenstein Global Trust, MobilCom, Pioneer
Investments, PricewaterhouseCoopers, UBS and ZDF.
Artificial Life, Inc. is headquartered in New York City, NY, U.S.A, and
maintains subsidiaries in Hong Kong. Detailed information about Artificial Life,
Inc. and its products is available at www.artificial-life.com
Also, ALIF ist nun in der Weltstadt New York. Aber man unterhält noch ein Büro in HongKong! Praktisch!